Geron Corp GERN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GERN is a good fit for your portfolio.
News
-
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
-
Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024
-
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Geron Shares Rise Premarket on FDA Nod for Rytelo
-
Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
Trading Information
- Previous Close Price
- $4.29
- Day Range
- $4.35–4.77
- 52-Week Range
- $1.64–5.34
- Bid/Ask
- $4.65 / $4.68
- Market Cap
- $2.76 Bil
- Volume/Avg
- 12.9 Mil / 11.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5,247.75
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 141
- Website
- https://www.geron.com
Comparables
Valuation
|
Metric
|
GERN
|
REGN
|
NTLA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 24.92 | — |
Price/Book Value | 7.99 | 4.40 | 2.46 |
Price/Sales | 5,247.75 | 9.38 | 44.05 |
Price/Cash Flow | — | 26.51 | — |
Price/Earnings
GERN
REGN
NTLA
Financial Strength
|
Metric
|
GERN
|
REGN
|
NTLA
|
|---|---|---|---|
Quick Ratio | 3.61 | 4.40 | 8.45 |
Current Ratio | 3.67 | 5.27 | 9.03 |
Interest Coverage | −21.39 | 49.94 | — |
Quick Ratio
GERN
REGN
NTLA
Profitability
|
Metric
|
GERN
|
REGN
|
NTLA
|
|---|---|---|---|
Return on Assets (Normalized) | −42.49% | 15.57% | −26.32% |
Return on Equity (Normalized) | −60.00% | 19.91% | −31.79% |
Return on Invested Capital (Normalized) | −51.31% | 16.29% | −32.85% |
Return on Assets
GERN
REGN
NTLA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Rvskykwnp | Xnpzj | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fljsqnh | Qhtwrtr | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nwfcwqtqc | Tdrrd | $118.7 Bil | |||
| Moderna Inc
MRNA
| Pctcjbqx | Tysc | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qvmgrhwlc | Hlhky | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Gypmrynb | Xhpxc | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Rvmlrpvy | Xlml | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Zvnzpjsgt | Gpbpyvt | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Sjmrrhxjd | Tnwj | $15.0 Bil | |||
| Incyte Corp
INCY
| Kzhwlhwj | Dfjdqks | $13.5 Bil |